0001193125-24-070838.txt : 20240319 0001193125-24-070838.hdr.sgml : 20240319 20240319084453 ACCESSION NUMBER: 0001193125-24-070838 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240314 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 24761201 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 8-K 1 d800974d8k.htm 8-K 8-K
false 0001567514 0001567514 2024-03-14 2024-03-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 14, 2024

 

 

Intra-Cellular Therapies, Inc.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-36274

 

Delaware   36-4742850

(State or other jurisdiction

of incorporation)

  

(IRS Employer

Identification No.)

 

430 East 29th Street
New York, NY 10016
(Address of principal executive offices, including zip code)

(646) 440-9333

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock   ITCI   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Michael I. Halstead as President

On March 19, 2024, Intra-Cellular Therapies, Inc. (the “Company”) announced that the Company promoted Michael I. Halstead, the Company’s Executive Vice President, General Counsel and Secretary, to the role of President, effective immediately.

Michael I. Halstead, 50, has served as Executive Vice President of the Company since January 2019, General Counsel of the Company since July 2014 and Secretary of the Company since September 2014. He also served as Senior Vice President of the Company from July 2014 to December 2018. From July 2005 until December 2013, Mr. Halstead served in a number of leadership positions at Warner Chilcott plc. Most recently he was Senior Vice President, Corporate Development at Warner Chilcott where he directed the company’s corporate development, legal and human resources functions. Prior to that, Mr. Halstead was an attorney at the firm of Davis Polk & Wardwell. Mr. Halstead received his bachelor’s degree from Boston University and his Juris Doctor degree from Villanova University School of Law.

In connection with Mr. Halstead’s promotion, his annual base salary was increased to $636,540, with a target bonus of 50% of his annual base salary. Mr. Halstead also received, pursuant to the Company’s Amended and Restated 2018 Equity Incentive Plan, an annual equity grant of 36,717 time-based restricted stock units (“RSUs”) and 12,240 performance-based restricted stock units (the “PRSUs”), each representing the right to receive one share of the Company’s common stock upon vesting. The time-based RSUs will vest in three equal annual installments beginning on March 1, 2025 and the PRSUs will vest based on the achievement of certain stock performance and operating milestones. A description of Mr. Halstead’s employment agreement and his employee proprietary information, inventions, and non-competition agreement is included under “Executive Officer and Director Compensation – Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table” and “Executive Officer and Director Compensation – Potential Payments upon Termination or Change-in-Control” in the Company’s definitive proxy statement for the 2023 annual meeting of stockholders filed with the Securities and Exchange Commission on April 28, 2023, which description is incorporated herein by reference.

There are no other arrangements or understandings between Mr. Halstead and any other person pursuant to which Mr. Halstead was appointed to the position of President of the Company and Mr. Halstead is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K. There is no family relationship between Mr. Halstead and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company.

Retirement of Lawrence J. Hineline as Chief Financial Officer

On March 14, 2024, Lawrence J. Hineline notified the Company that he intends to retire as Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary of the Company following the appointment of his successor as Chief Financial Officer. Mr. Hineline’s departure is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices (financial reporting, accounting or otherwise).

Mr. Hineline has served the Company (and its predecessor company, ITI, Inc.) for over 20 years. The Company would like to sincerely thank Mr. Hineline for his contributions to the Company throughout his employment, and for playing an important role in the Company’s evolution from a private to public company, and from a development stage to commercial stage company.

The Company has initiated an external search for a new Chief Financial Officer and Mr. Hineline has agreed to remain with the Company through the process to ensure a smooth transition.

ITEM 7.01. Regulation FD Disclosure.

On March 19, 2024, the Company issued a press release regarding Mr. Halstead’s promotion and Mr. Hineline’s intention to retire. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number		    Description
99.1    Press release dated March 19, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

INTRA-CELLULAR THERAPIES, INC.
By:  

/s/ Lawrence J. Hineline

  Lawrence J. Hineline
 

Senior Vice President of Finance, Chief Financial

Officer, Treasurer and Assistant Secretary

Date: March 19, 2024

EX-99.1 2 d800974dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

INTRA-CELLULAR THERAPIES ANNOUNCES EXECUTIVE APPOINTMENTS AND LEADERSHIP CHANGES

NEW YORK, March 19, 2024 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation. He will continue to report to Dr. Sharon Mates, Chairman and Chief Executive Officer.

“Michael is an exceptional leader who has been instrumental in Intra-Cellular Therapies’ strong growth over the last decade,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “His knowledge of the Company and broad industry experience has contributed to our success and helped to establish our strong foundation for future growth. I look forward to continuing to work with him in his new role as we further build on our commercial success and advance our broad pipeline.”

Mr. Halstead is a seasoned healthcare executive, with deep experience in various aspects of the biopharmaceutical industry. He joined Intra-Cellular Therapies in 2014 as Senior Vice President and General Counsel and was promoted to Executive Vice President and General Counsel in 2019. During his tenure, he has assumed increasing oversight responsibilities for many company functions. Prior to joining Intra-Cellular Therapies, Mr. Halstead served in leadership roles at Warner Chilcott plc, including Senior Vice President, Corporate Development, where he directed the company’s corporate development, legal and human resources functions. Prior to that, Mr. Halstead was an attorney with Davis Polk & Wardwell.

Intra-Cellular Therapies also announced that Senior Vice President and Chief Financial Officer, Larry Hineline, will be retiring after more than 20 years of service. Mr. Hineline has served as Chief Financial Officer since June 2002. The Company has initiated an external search for a new Chief Financial Officer and Mr. Hineline has agreed to remain with the Company through the process to ensure a smooth transition.

“I am grateful for Larry’s significant contributions over the years as ITCI evolved from a private company to the fully integrated public biopharmaceutical company it is today,” said Dr. Mates. “On behalf of the Board and the entire company we thank him for his dedication and wish him all the best in his well-deserved retirement.”

 

1

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Cameron Radinovic

cradinovic@burnsmc.com

212-213-0006

 

2

EX-101.SCH 3 itci-20240314.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 itci-20240314_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 itci-20240314_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information
Mar. 14, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001567514
Document Type 8-K
Document Period End Date Mar. 14, 2024
Entity Registrant Name Intra-Cellular Therapies, Inc.
Entity File Number 001-36274
Entity Incorporation State Country Code DE
Entity Tax Identification Number 36-4742850
Entity Address, Address Line One 430 East 29th Street
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code (646)
Local Phone Number 440-9333
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ITCI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d800974d8k.htm itci-20240314.xsd itci-20240314_lab.xml itci-20240314_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d800974d8k.htm": { "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20240314", "dts": { "inline": { "local": [ "d800974d8k.htm" ] }, "schema": { "local": [ "itci-20240314.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "itci-20240314_lab.xml" ] }, "presentationLink": { "local": [ "itci-20240314_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-14_to_2024-03-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d800974d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-14_to_2024-03-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d800974d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.intracellulartherapies.com//20240314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-070838-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-070838-xbrl.zip M4$L#!!0 ( )I%)%(5]XLDD,R6C+!#8LLJP)OL?DDU,XWH]3 ]Z1X$[*]_ MSSD],PPW@24A)5F[$DLP?3E]KL\YW3V^_,=L[+%[H8U4_IL?2_GBCTSXCG*E M?_?FQZM>J]/Y\1_-H\M1",V@J6\:KI!O,J,P#!J%PFR@O;P13OY.W1?@0:%< M+%D;T+N M.\F,DU!OI:]>@*<):495RZ6S!Q83M4@ZS+:U+4%;'Y8N?GO;_;!H'FYNOVA: M %[X9JCTF(>@/#A2+59Y[I?+@OWUZ'(L0LZP>T[\,9'W M;S(MY8?"#W-]4-0,<^RG-YE0S,("#5> 7@4[(&/L?/2E??,A'-/O,FX MT@0>GZ,EB$R37_"_^$[C]]% M%,S"KAC"XXDF[OZ.>IHK5G*EZN^A2GW*,.F^R]L'ULQ; HW$Z_BNF/TBYID4?5L:?!V=S2*84.WTK%:JKM-7 M6&&3%D.AP9\) Y_1O!N&# _F.J3WH)G07[W)&#D.O.2[D<9%HE_)Q0XC/S-N M_)AK1RO4A-V3%*+5+JV0/ALUT?8CV4TC8B]):P_VQMT$"2OY*%W\8BB%9L1" ML=&J6YU?E@6TVAFIWCA^ !)4;O(1#%J'USP4S05M<<_%LP6M[I:V\9-DVF2> MPA)W$FXNN%=(FU\!S!1^I(P5>^6X)^_\A@-K$3JS_'PJW7#4.,_7I'^1:NN) M87@QYOI.^CG\O<'X)%3Q-UK>C:*O<+@@'@Q]96XDZ"G$Z" 9(E1!(_5QH,)0 MC>F;@=) >OQ-*9@QHSSILN^*]"?3_.&[TFGQXK(0;)NHLGNB\J,G2@U;A4'8 M^@+8$$23,_*_HE$Z3SX/^5AZ\T9?CH5A-V+*NFK,_0MZ-K5T#Y3G7FP0S^>; M3K]]S7K]JWZ[MYV/'3J_7 M^73S)!K+ST'CK]R, F&RL^RZWPKS\K%6K6^0M?*I+LTUTOIAD M$=X@.5T1*!VRX_BSX !OA F9N(>63--CX9XT=GN'6\)(;0N=OMI-V$P.7478 M<&& ,70?N7P^!XJ$GW8C9YGF1X"\(U:J9AD.\?0^^V:I'-\KKB M3AK,[,,;>/*$6'.>:78P8%ERSK^$Y^A])\G>\H/@=KCMLS#CX" M68*6J!-6,&Z8"82#J9#+I,]D:!AX%3!,O>KSOBG[\X3/9Y%H2XW'TF"-E+V3 MGF"@:P.A'W"EU@BPK6WZ! .H8T9=RE5.RV>'=)!'ER$?P-*PO&D"[F !.%/, MT.> NV[\.9HJT@)'>1X/C&C$OSS,ZY1@$.U:/2D5B]]'6M4H1E0VBG$2#'1I M^MM=SJQKQ>^Q"))^<"]T*!WN1<*S"XTG66MMOZ^>XX/+0C2)CI\&_$[D!EKP M+UBDE:YH\'L%*K[W^DK$X*4964JSV)(Y-,@0V,H"0'#@9T$8_I* 4[JZTPV# M@U0:(C^I6R^$<-Q2$W"G\Y9RGQ3:L;"+E9A0!%K=X[1+L;T*>?^U\/@48OZZ MTN*2D.?N'O);*.EJ\X.P,_UX.I*AR*$Q"*!_"D%G)[_[?-:)BET.F(#WVO8Q^L*J=/ML?8X\-17RK(ALQN57\B%K S^ MPI#Y5XW !(V>$H+K];]U[+QR72V,B7Y\ *1<>H(?+V>:U4J1M3FDY.5Z.&*] M4 L1/A0<_^Z<;<&OGW1?3?TG\+62:>)*_Z7TEU5>9G?A\X@."@V?]"T &4G; MR(\FI@K$_&O7MND6*FX5P"GOWS)X%#1;T%#+-,&<2Z,*1/)$A3@%MIU63T_VU\L/"J1R.U+^D[/7ZAFXO6HQ5Z]4*L]9J'D>N+$H M4OWPW7FY='9A0&<]$>#*F4]+3VL2Y#(\5J6GU'V?16MN5,AX$'A@0*##K\]+ MW'@"7&V+7II21?C(K;D"%X?,EL_!/:"391X&0EN5_E;Z>IW25Z;9&@GG"VUT M@"II!1X5DZ2!FK&!\-04I88/:5/Q//<+&TH/#4$:L(I0^"Y(,U0@T/'$"[DO MU,1XK/O\'4GM:A+*ED7+GNQ;5\[B9)H1 M;X 9:>:P(+5#V9V NE3+M4A55S8&<3_PN'3&6N^ZK%PIYJ'AUR2*W_1WM_[V MP,:Y43BGOTE9VHKK58MZV M_*:]SZN]MUJ@Y\53FG3X!@.G_C0)?28N!03DGQ:&=OKA4=7/E MX\')?CIMVW[3ZH-J=<>8B= OHMNEO[=N5T2N>NSLI]M1V]VZ_>RI0PH 62PO M-&0#P:9S762I$;:'%6R'\G_^FOE3=ZTKU?UVK3=O5E?*S[+G;8?Y<]0 ]TBI MMRQQP^;LJVX7]?%>D#UYYXR8XW%C7F8;[[$L?.7-OK[F:)ZOOLW7FX_AT;%Y MH4W7OZBT;J+#;*3<(HI'KRX[B"[@!X"B10A:CH1_TMVSK7FN#:KS4GE [N3Q MA?=:V9Y: P[U0N6L[8V]TNF;;0N/G(&UQ2>LNI)I=OJMSI]\M;&88USWJ".R MJW 9C7+M'%:M"HX68-<--R[_@[WW%"!J0&8>8#/VD>LOFW:@7Q)&=GP7H;!@ M@SESJ!H-(WX!JQ9T3&>E5"P-XSX#'(V3WK$[K:;A"!%U@.5C;I@KAM*W9VMM MT:Y88^M'^1PJ,=>]%QM_?4JV4['2Z3JSV0R1V6/YWA YJ$FWX;U5*N M;5Z,0.G(FD#I?$5YS\0(:@4,B[9(\(*[I%S(7C]%!M%^J&IWWJ+]MZ.CS7HHQFMJB%^E4,9 @* !97A3/C<(X&#HH\M1 M D@@_52Z\5V=_ES$JPEFZ8)/@0AX>%?S>>\='[W<[0F,UNV/N/E>+%W4\L4R MNQ8!U^%$$]B\EAK466F#5M&"",O!KW^B(Q[:7+"V%RE[NND%NPH")?V0BBWP M9+T?NC7A&P[-Y^Q*:S0-;&TV-<^S[:[H]" L6:'_(^!;+CS6R;.?N <@E[L8 MZ6ZU,'2O_K#T99J??$:WM*QUE.KVJA;>O7GH5@X[1L>#DBT7+Z(X0I]*%R?@ MZWQP9PZZQA$/R45%3="IC14ZTPW+SJ9;)B:/(9' MW@T,!8X3_:,6(=?@X\%;DC-7-FU/=13#(6H6#"G'8^'BIK@W?T@1GBP( M#9Z4H1Y N6! NTK1VQ.^!/M]F-@AR#TU,G!BCU[K8$8R8(&RD1F 91(0ZE'I-#Y0!"V*WROMA^/_!Q<('K<*=@\OD- R*/)'(;@>Z VR"Z):L MQ15W6@@KY[? 4G#;GWU);YX*YW8QT.UG/);/KA6Z\J4N_Y2>QWUUS].]>LX( MD"52^X%/#V^?'3PDX/M1T"'4ML:%9+W6D4E\<\*(TA8P0X_ANUN8X1Z:$PH M3 B0@K'G:/[OM'*:K57!X"TB9&!U=R)D ^5/*#;5BM_CC\WC;1()66(LE^P2 M4-SD2ND%0FBT((VNH-L]+ID?:_\Q08:#9\!Z;D$:6=(?2XBP#>X(% .- ML)*STAD+@8>Y 2T0M#0$9(]#&JQ(@ GC]Y]-*D"XD'!E(7]"Q$SI M!,R\8Z!4P+E-CY:U12LM N@I+(HFQX\Q%UD1,8CAJ3\SXA9[;.*/8PLJT:P! M_'H/M,!X>0Q_Z<7B_"!%SZ,6Z'_"$>HRL(E,EWA&[ZWR/ L]!I!3^#X=EEH. MN!1O:\02I.EV96@[G\()A.T!BY7@+F+\X$2 QE*=8B<-J> +;L\/2$^@60IP M'E=@>\;1,HCAU78]%W1=P_HY-%?[6V3.]B&LVQXNLV%$^LG+OC#1PNOIZ+*R MU&OG!2Q\ QSZ21%*>W>'#O6FYJ;#:7AD$]ABM] BI5C$S0C;T80Q<%R@0EPR M+:]TP6ZX1O9 GVMI'$\91*:89DW&8US+4J<^;47AH._1#,ADT4YR;TE&5U-* MVZA5I)O4^ GDW2I\QQAFB+=\;O6(U+(O]!B21RL]O9NI.QNT*'_,@??$MYP! M9(H6L'P!S>KYNMU054;2VD 19G-&KH6DA9DP=L$W <9V,1:"-!+81TH[ E@, M'A\/$P(;R3>N%&&04TF2F[JL"_]=@=YY5G?+YV1+ !1LT3BMXU9KXG@+V@OQ M&58#Z7_RAJW#!Y@^H0)T0+Z*[JGQI?1$6XVF&@!P"+U&.!7"W^3Z?=>>J:1A MP,H-EA]2 <#R8 LNL"F(#4O(ZQ@F+0'E50R'4ZZ/!YS%P@AGF-C-<4!L2S41 M;B,I)0%3-?'0MT,S'7C9!K<8)ZD8R017MVQ>6)($*")_MH69C,0&N^,'TQ2Y49+>M.\OZB.U MAZTKOP*?A)8;;D^I%B>?HS/9Z4( !E0S<0#G&Z!G.[_30#!:=LH3Q^65R"S= MB8A-$FQN$443+QN3IGQJ!'$[%#HR&J1S,Y*,8 6%]8#.* IR7X%&F\=4Y7A1 MW;2W &"T;+K0&5_5G4HC3EX@^5[E63KK3C/B&&6)@!/@I"LB:22%XTZ_8PL@ M)Q3:U#TEIPQ??F,L2HS'L0[/DU^$/4,/J@1<)67TOZR+D(:C+00,P'(PL5GK M,O\19:K)W4A-PA3^LEDCDHUCX"M&Z38+!+TQ,AXUDHH@6Z*WN%<>S68S,8X7 MK^XQ*86Y@\D A+M8/DUB6Z525HSW=]2>3D)IDKK]SMG#ISU7;$VX-*+,"P(: M.6C M@$VKE,33ER[9)FH3.!*L*N!&%>0<:.U[%"HVZW32CH*CQ6MQ>,1$T5%!$L:6 M)Y=8C]*^-*.X;CF2 QFR>CU?LGX+6K0F6J.'B%Y?ALRE-QCN G7GRZ NG51: M/P9C$V9$X47Y06KZ!6$("-'_CB 3IX@XP&H;!,$D,:.T(T[8R(-.($TP@O*[ M:+\MDLWYGAO$6>0'CZHMZ<)%NO&B?I$.A0 !!O_!W?O(\WN2#Z1GIZ+) O;3M5-3^)W-W$'J]J,2LW=*/)+M!>=?X&-_FA0>%K4\@8J'F A?+ M+_;VDO7381NYA*'I,**QY]$XLR^@=\^+Q?I9U16S>KV4'X5CNJ:0"MTN188- MJ -<"=]VO/+O+)E2L7I P;0H3;S%?*B#ALWMYO,U#[E]W^ Q[G*Z;E3]C/*T M#OT3&@S_#0WF1J]N/4G937)\[UOB\+KO ^UUWM]<]3]WV[V#9[FW*SM\43TU M.=VR%S;=<,3-Q8UWAT]HIQ*QM:W9V!HF,[!:NPDE:2<+$.V;K]6!*=1VE6/WY5KM7^\.'SAZLNZ__4[E[==MJ]+.O!_U*[=IGG)Y:9^JW=Z;0,N*G\"VP[_]!U_OW]B"\M?+ MS9<%^P^6T;]EUOQ_4$L#!!0 ( )I%#DY,2YH=&W565USVD@6?:>*_]#%U*9FJ@ #\7ACAU!K PED,;@P MB2?[UD@7U..66M.2P.37[[DMB>"-[XY]R;=T>)RTNN. MAN>#7K7278P7DV%O^%OC]+39[A[EC_C^J#@@NA>SP1=Q\:$_F\SF[VHWH_%B M6!/7BR^3X;N:5A$U E+K(#V;&AM*7>N):@7O]RE*R?:Z@_'G\O!6^6EP]J;Y MJXIJ0FJUCF" 5FG-77-5'@NE7:NHD9KXK!6G;T7QO#1I:L+\JY6)TD:BOM)9 M^]OS2H9*[\X6*J1$3&DKYB:4N.E\,OXP?5>S[&2MU[WH#>\"M52IX(A%]^BB MUSVZXI ?\J#=>087^-+Q=#$_;_2'D\FGR?E<+$;#^?G5>'@MSJ?3V:=I'Y^& MOPW[GQ;CST-Q?G4UPPN7P^F"#PS$!,48SJ]'XRO1'YU//^#T7^+X='@COLSF M_ZR+2VF]X%6T3.*W[=.ZZ+0ZQ^+HPV1V,10X='TSG@^/Q*N?VK^VWXIQE%K9 MZ)/6F996+ *R,E:4U/&+UQ0_3V7BRS_.Q'C1'_]2%U(LE8D#"?AXE*7*DUIX M)HQEM(-W7I:0+TPDTH"$3QO2)@X!KFI%1CZ?"\EZ"G#Z*E.%8V;%)W&A,Y7 M@A4>L4=:1&0W)DM$LDM2"L7/_>GU+\)7B;$^6;B7&E_NA(PBDT4>;N4K8VM" M4UJ^5%X@28N1U+ @_;KXV!PT\5Y^U"2J/'EE*5$^[FV*2]O,$U>^)50BO,Q: M_*IW(H%3*EH+F8CA'7GP>D/BL_+HFPW!H7X@N"]UM=*'=PGI)K*):V$KHBWL M>)9D"J\'Y1!Q5Y M.O/934UKJ>LBR 0 0=-9CTN+1ZSE?32S.)4?M\K&<9O19+%,;L72!75Q1\9 M2I7NZJ["6DGDN0[K*R8/E[N4O" RVJQQAL.F._!(Q'$KU&7C#C7%B/(@/*!7 M11EQ"2S%QJ;\:5!&? U4P>8E$@,7^W#!LMMLMQ\H6AUD?+9:(>>V*;BI'J:C MY^DI-,GQW]^62$+YX!#=>11S9*A#7C^Q#8P(9%*M+(DB9"A);<:XQPG4YK$6 M8^,GR'F*L-=B;5BTS +E:026!+@#( M \(2]W9 .N;&-(*25"ZU2H+\3![P"JWAYSCBOE]E@",5:4"_"&W,+?^RE=89 M*>##N,;3UMA;!WX1J)"S7#27ZR/NSRW!I&5Z$=3ZC3P)+)$92O4\QSX1/%A>9"/C;2* M^5,F,7EI4I;W>_HNR^L:]7>C^*K[R*E6]M!ARYU6^Y@S?$V10N$>IS]1L)_[ M;HLW#+3%*@- X#$9QH$LTNAA\$U64'GX0Q^\KBQH7(EA$E+,+ M=VGYKG_XKI.&O$WOJT.U\D J8%BF#ZJ3=)PH 7D$MLO1.) ;U.?*Z-M#;4'H M_A8I?'G6?JQ<&&03BYO2T(24^7P*5<00A$:E >7,'C%CJ1U7>AF"(\.9XW"D,-Q@1]\>N1Z 6P# M'A\SO-!IM3I-#G!/VVP"H$V5FR^<7.6:S#R"L= A7SJF=/:KE>\OX-@?=DZN M+>7M:RG$C)#7^U VTL":;!V4XYCC5U: *&%V!YN%QO K5D;Y /97B?A8R!#J M@K2L,LU9J%9<&5A%+,F;A,\TB6DKL;LI)!";TGQFAL.\QN/-X^+/Q.\4L-GT4 7B#UJB3X M"\-ZR27D)T 9W+"WO07&&9"W3C49"LRD/OGPP"FQ8VH6:OY= M5.,Z#?I<1R M!S=\*E#J $_,*(U\>YN.P>,Y5TW.[;ZW7+CWG M?1J+,/:U8BU&,.XO(DK2G:;["*7P.U?XJUBNJ;&$$-TVEH0\TYG46[E+L')W MCV*>(T9S<3W^%P)[72OMNK7][*=3]ZA=K=UJ_6WO;A]KYG#^/[>X M\]9\OC19FI?N40+^P2)\\I+LG[OF1JJG=E@,I0!V]_ULNMCG-% I-9(8Q\\P M+L-BW-[4+$GG'\$ 7ZFQQ>H#">@>L84>ZVK.NRPVV(.U-MM$9(X4^2J+ MT9A%V&R+5=CIU&H%/7>]!VMD&SSMPJC3#P^1N3G,M:;Q=[D E!%HMR*N8<7M MFXJSX97)D#$X6;(WIAP'1+FJ81)+>2WE;LX'I)A,C&%:*[?S.JIWFR#=B3C9 M>0$TQH+*V/^(,LN+(!ZQHV/^8H9Z;W(-Y'5POS36,?/P[P(S JBN^ZFWW6Z; M]]S<)Z*)Z[I'GWI/:L2;9\)O'[]C)S[[KX*T^&>7E^6^WL<,@\$U5#^@KYCJ M^)]%G@CX6:Y\?*3%Y!!F42% ^3(VCC:0'*!G3KKX^H4SDO=[M?)$Q_^0$DZ. M3QK'QZW&Z>O7KXOV+UG@I4>7P-1,CI T4O6M"^Q26-HF$LL+P9# M[4M7R;/E3?]80@:_X<#4^?I@0DD M.AM\P9?NOS#^#5!+ P04 " ":17-8"Y)M9$8# !W"P $0 &ET8VDM M,C R-# S,30N>'-DO5;?;]LV$'XOT/_AJJ<-F$3)3@=8B%-D2P,$2+/!38N] M%;1TMHE1I$922?S?]TA)CNS$GIL,\XMIWGUWW_VD3S\\5!+NT%BAU33*DC0" M5(4NA5I.H\;&W!9"1!_.WKXY?1?'<'%Y=0,QK)RK;<[8_?U]4BZ$LEHVCBS8 MI- 5@SCN]7^__0)?6^LYS% BMP@5MPX-_-8(6>:C=#3.TFR4C(8P@]S;@Y([ MS&',L@DCQ1/(TCR;Y.D)G'^"C\&,@EM1X1"KZ[41RY6#GXJ?(: NM%(H):[A M4BBN"L$E?.XI_P)7JDC@7$J8>9@EGA;-'99)9_7!EKDM5ECQMV\ *&'*YHI, M-M4T\IGH$O$P-S+19LE*9YA;U\A(*28M-**(!M!_QSW!4"6\Q&Z "V[G =1+ M?'[& X1PA=AR(Y0SO* T-)(;MT+#:X%MP7R2TG%V,H"7^(@.!"T6R5+?,1+L MNO)R\7Q(HS0=,^H/1UG' 40*]?*E-=8$+WDA"->J?ADNQ$%@&+>K;"I7;TMG6<-PLT=WP M"FU-27Y%XJG9GHN2B&?LKT_7GT,?1F<> !!:4U2U-@[:#KW619B< \GUO^*^ M)K&_BK-1/,X2,A:!>C:&/04%]FHB?:E?1&33)T<3L?OZV1]B?]CG_?DI>'$& M=H?=QS_Q\6>_'A7_DV7Q'S#1ZN:U9 8;[^4U45P4[4)KC\?7Y1'YJM[L=X3/ MP_N#CG>72N=/,,%A&66#F]I%QN3/MVF$:6\BX'X_D_AUL;_-%P"6)IUX>R[8_ZSX'6#P?O_=R2 M!OC#E]G5L:_%YKE@CC]HI:MU2_E"%XU_G_KOH_]#>PMS \@ W<:AX"[Q3L>^KN9CC][56[?>CG=U!+ P04 M " ":17-83)P(WUT& "_0P %0 &ET8VDM,C R-# S,31?;&%B+GAM M;,V<74_C1A2&[U?:_W":WK32.B&P-T3 B@:H4/D29-NJ5;5R["$9U9Z)9AQ( M_GUG_+$X9.R,F>.:BV6-?!Y<'9Q>0,>S)-D(4>#P?/S M#P SROBQY.O\'M6;@3W)"*^)!#[,B$"?EG2*!SM[^T? M#/>&^_W]"A:_@27+.C#:13!O4Z3JD])Q!,) M^[EJ1-F_(_UCJKN'CQ\ U&ED,MUWW-,G(S\7JZF(^ES,5+-[!X,BI?>2L=I* M>3Y($X:'AX>#]&@Y6E)3K!(?#OZ\OGH(YB3V/77ZU<,5Y&4D'&T>B^/ M3]8+%4]6"6$AR96_:_,@CYH+\IBI:OA224F"_HP_#4)"-2$'>L/3&[K#']4O MW\9<\7XZE8GP@V2S7J1/$1?%SM3$<<^0--AL2,>=BF!#RQ=!H:,V=_C/(P8! M5X_;(O%2Q2+]4?#8V$5>CAL.?HNFD;%-39+:TN--F/?U89?73*AL3!#)ET+A MU>2A3?VS.D(8&/C?/N8"Z[;.DB4%L*@E9W1Q&^S3*1EKS@8WA%!>7C.PC/U>J8I MCZ^2.P;3;(77!&&@:A#$9C8K :H&Z")H^+;0NI%CZ_XQ%@OW9$;U(IDE-WYL M3;0YM].E0H417AWCOE PZ>&N$UXJ@"Z!M$IHHV_#(L&Z>0R0+VA$;I;QE(AF M$)?S.@788(";C[N#^UH+%UJM#ID\$K#8_1I@M6H: ]1+%G"QX")]3^\A45?X M,5^JU?1ZS,.&%^ =4IWB;&>36Z>X0V\ACSL'&P4AK0AY2= UD8;C?_!EF)>W MF\,8HHF_N@S58HD^TNS-\;=<^BM%.AV<7=:X1;#[L-0*XXZ)*@6;M7"?/%JU M8IB,-_C!&(G3,%0&9/[?%65DV&PFC-A@']-WA!1'^L-F_%A#^S-X%?3G\/V!OLF*!_"4-#_K5D2\#K,L % MZ$*XL&,;J$/=S@4BYNE:ZU;<"?Y$6=#P)4.5QGL OLJ8B?I7L6CH&W5;XC]; M-"MTBFJX0]"*E;I):. '<1SNN$S\Z"^Z:/[ZV:SP'D;!;,HT"!N1:&-@4&UI M"+)*H$IAOB9NST;= %A[<;P12AL4Q&\"_&9.5[=!F1KGV\><;H+:TD$"-WV> MU\HXG.+WN7$#E&6S;B#J.Q.CNSEG#=]YW\[K",A* ]Q\W 5,LQ82G*DXI.I8 M;YZTTV\9TB9-NX'ZAZ!)0MB8Q_&2Y6_*2%M:*Y([0K;>"J\)#><''M& )I3-KM6*6U _LF79E-D1R#4F>%6$"\)5:DC\ MOLA#H>\,;ULME\EMU+<;MG>"Z/D@"HOT=C#]%0%Q^_AHOW"H4^@(8PM3?%>D M"]:[5)'P5F6@7 >R0I!6<@:];1-EX-_H!!7]2RF71+@/@$'G?8Q!M4'S,&S% M(XY$A79;@Y&5:W4^6G)4.R6-;#DN;TBP5.NI]7!_.J%)9/T>QW9>5TN;*@/< M?-QI66/4PEK4Y.*@U"&5=U_3M-+OQHJF0=-NH$Z$K[]P^[".I]QZ"?XJJ2-$ MS:USPT$7. U"2&3FRI!).U/90J-E)&V[Q;ENGJ^"N7)+FMS1;<[M^/II-,*K M8S"NH]MZV-?2H@+.'=WM]6V\IEHVC_'YWGE,Q$Q-S:^"/R=SM1A9^*SAMQDK M)#K]A*_>%M\9ZOX97XTL$NOY!V-%(<@J05X*Z3.^%FT8/N2S]5+><:6V]-^= MR'?1[*\OJ#W_ 5!+ P04 " ":17-88#4V$KT$ "9*@ %0 &ET8VDM M,C R-# S,31?<')E+GAM;-6:78_B-A2&[U?:_^"F-ZW4$ *S;0<-NZ+,S IU MO@1L6_5F99(#6'7LR#8#_/L>!UP1"+,P7:UB+B X?H]?G\=Q$B=7'U89)\^@ M-).B&\2-9D! )#)E8M8-%CJD.F$L(-I0D5(N!72#->C@P_NW;ZZ^"T-R?3MX M("&9&Y/K3A0ME\M&.F5"2[XP&%(W$IE%) Q=_?[X$_ECTUR'#($#U4 RJ@TH M\MN"\;33:K;:<3-N-5J[,@74QB,I-= A[2B^C+#B!8F;G?BRT[P@O7MR4X01 M9,PRV-7*?*W8;&[(#\F/I%!=2R& (-J69HM]F.G"C8 MU:P.1,MV(8DO+R^C8F^YOF95M;&!./KK_FZ4S"&C(4) :,E>4^@F-?^I=\V] MBS8[77W-.KJ(=">3(O)AHEN4< M A+M]"Y7.)*$*6K?84%) "L#(H74A;$=^";]?[\AOAW6,BGEPQW9!4X-26,F MGZ,4F&VQ;3=LLMI%HO#/Y[[$R:0WT=:I*2>$VW$DE2OD= *\&U2(HJ]IJ(?= M3FW7;SF=G6IH3U0VM NQIY)22*H2%PXW#PB6CXEMC2BG"N.%R1RG/Z>>*IE5 M)F?;FJPT*E4*JANT6@V<"P*2*R85PL:2@"PT>I&Y=4VYW0=34 K2NTVWC[HL M+.*\JJ&H^97Q;$9C'^S0Y@,<_JO?87TJIB/B^N(Z8MAA:WN#S+\,\7DH*P/4'6.E:8%Y4_T9T#T998MQ/8:69\*ZXBXOL2.&';8_%ED&4G.$F:8F-WC MR5@Q:^TT9E7*^@*KI+[R77 MCJ(_ZRE[O1EHO0#U_UE6Q/&&:(7W+=<+?Q961I LK,6X-1DSPT^^E#S4U9?; MH5?'R9_5D[&B]A6LT3J;R)-/=WNB^A+:,^KP^+,^XH;8S2J94S&#L/245 Y< #@ M @ $ 9#@P,#DW-&0X:RYH=&U02P$"% ,4 " ":17-8 M$LP5<6P( #)& $0 @ %1%0 9#@P,#DW-&1E>#DY,2YH M=&U02P$"% ,4 " ":17-8"Y)M9$8# !W"P $0 @ 'L M'0 :71C:2TR,#(T,#,Q-"YX&UL4$L! M A0#% @ FD5S6& U-A*]! F2H !4 ( !\2< &ET I8VDM,C R-# S,31?<')E+GAM;%!+!08 !0 % $ ! #A+ ! end XML 17 d800974d8k_htm.xml IDEA: XBRL DOCUMENT 0001567514 2024-03-14 2024-03-14 false 0001567514 8-K 2024-03-14 Intra-Cellular Therapies, Inc. 001-36274 DE 36-4742850 430 East 29th Street New York NY 10016 (646) 440-9333 false false false false Common Stock ITCI NASDAQ false